Novartis expanded its RNA therapeutics pipeline with a multi-asset licensing agreement worth up to $5.2 billion with Argo Biopharma, focusing on small interfering RNA candidates targeting cardiovascular diseases. The upfront payment totals $160 million, with milestones and profit and loss sharing options depending on geography. This deal complements Novartis’ recently acquired siRNA assets and reflects strategic prioritization of novel RNA-based therapies to address high-mortality cardiovascular conditions, aiming to improve efficacy and dosing profiles for patients.